BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

EnWave Corporation (ENW.V) Signs Research Evaluation Agreement with Merck & Co., Inc. (MRK)


12/12/2011 7:08:08 AM

VANCOUVER, BRITISH COLUMBIA--(Marketwire -12/12/11)- EnWave Corporation (TSX-V: ENW.V - News)(Frankfurt: E4U.F - News) ("EnWave", or the "Company") today announced that it has signed a Research Evaluation Agreement with Merck, through a subsidiary.

Under the terms of the agreement Merck will conduct a field test to determine the feasibility of the Radiant Energy Vacuum ("REV") Technology using EnWave's new multi-vial pilot-scale equipment. In addition, EnWave has granted Merck an exclusive research license to use the Company's technology and licensed patents for the duration of the evaluation and an option to obtain an exclusive commercial worldwide license to EnWave's portfolio.

"We are very excited to begin a research evaluation program with Merck," said Dr. Tim Durance, Co-CEO, EnWave Corporation. "This represents further progress towards our goal of establishing REV as a viable commercial technology in the pharmaceutical setting."

EnWave's dehydration technology portfolio for pharmaceuticals and biomaterials includes freezeREV™, powderREV™ and bioREV™; each employing a combination of microwave energy with a low pressure environment to achieve rapid, highly controlled dehydration of live or active biological materials stored in sterile vials or in bulk powder, with the goal of significantly reducing the process time and cost of dehydration.

About EnWave

EnWave Corporation is a Vancouver-based industrial technology company developing commercial applications for its proprietary Radiant Energy Vacuum (REV) dehydration technology. In collaboration with an expanding list of multinational partners, including Nestle, Kellogg's, Grupo Bimbo, Grimmway Farms, Ocean Spray, Hormel and Bonduelle. EnWave is introducing REV as a new dehydration standard in the food and biological material sectors: potentially faster than freeze drying, with better end product quality than air drying or spray drying.

EnWave currently has six REV platforms: commercial-scale nutraREV™ and MIVAP™ are used in the food industry to dry fruits, vegetables, meat, herbs and seafood quickly, while maintaining high levels of nutrition, taste, texture and colour. The Company is also developing powderREV™ for bulk dehydration of food cultures, probiotics and fine biochemicals such as enzymes; quantaREV™ for continuous, high-volume low-temperature drying of pastes, gels, liquids, or particulates; and bioREV™ and freezeREV™ as new methods to stabilize and dehydrate biopharmaceuticals such as vaccines and antibodies. More information about EnWave is available at www.enwave.net.

EnWave Corporation

Dr. Tim Durance, Chairman & Co-CEO

Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. There is no guarantee that the Company's REV technology can or will improve processes in the target industry; even if the Company's REV technology can be used as described in this document, there is no guarantee that such use will result in orders for the Company's REV technology. All figures comparing REV technologies to freeze drying or other dehydration technologies are provided as examples of data obtained through the Company's own scientific and testing programs; each product must be tested individually to determine the benefits of using REV.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact:

EnWave Corporation

Mr. John McNicol, President & Co-CEO

(604) 601-8524

john.mcnicol@enwave.net

EnWave Corporation

Mr. Brent Charleton, Director of Marketing &

Corporate Affairs

(778) 378-9616

bcharleton@enwave.net

www.enwave.net



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES